Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
04 April 1994Website:
http://www.prophaselabs.comNext earnings report:
14 March 2025Last dividends:
24 May 2022Next dividends:
N/APrice
regular market | 42 min agoAnalysts recommendations
Institutional Ownership
PRPH Latest News
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2024 Results Conference Call November 13, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications.
ProPhase Labs, Inc. (PRPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago.
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the pricing of its underwritten public offering of 4,170,000 shares of common stock. Each share of common stock is being sold at a public offering price of $0.72 per share, for gross proceeds of approximately $3 million, before deducting underwriting discounts, and offering expenses. All of the shares are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 625,500 shares of common stock at the public offering price less discounts, to cover over-allotments. The offering is expected to close on November 12, 2024, subject to satisfaction of customary closing conditions.
Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025
GARDEN CITY, NY, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today announced that it will be presenting at the Virtual Investor Summit Microcap Event. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q2 2024 Earnings Conference Call August 14, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Conference Call Participants Hunter Diamond - Diamond Equity Noella Alexander-Young Hello and good morning, everyone. Welcome to today's presentation.
GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on August 14, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value Creation Garden City, NY, July 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported that Pharmaloz Manufacturing, Inc. (“PMI”), its wholly-owned subsidiary, is projecting significant revenues and earnings growth for the second half of 2024 and the entire year of 2025.
ProPhase Labs, Inc. (PRPH) Q4 2023 Earnings Call Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2023 Earnings Conference Call November 9, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Yi Chen - H.C. Wainwright Hunter Diamond - Diamond Equity Dennis Waldman - Barrett Productions Operator Good day and welcome the ProPhase Labs Incorporated Third Quarter 2023 Financial Results and Corporate Update.
What type of business is ProPhase Labs?
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular and DNA testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
What sector is ProPhase Labs in?
ProPhase Labs is in the Healthcare sector
What industry is ProPhase Labs in?
ProPhase Labs is in the Diagnostics & Research industry
What country is ProPhase Labs from?
ProPhase Labs is headquartered in United States
When did ProPhase Labs go public?
ProPhase Labs initial public offering (IPO) was on 04 April 1994
What is ProPhase Labs website?
https://www.prophaselabs.com
Is ProPhase Labs in the S&P 500?
No, ProPhase Labs is not included in the S&P 500 index
Is ProPhase Labs in the NASDAQ 100?
No, ProPhase Labs is not included in the NASDAQ 100 index
Is ProPhase Labs in the Dow Jones?
No, ProPhase Labs is not included in the Dow Jones index
When was ProPhase Labs the previous earnings report?
No data
When does ProPhase Labs earnings report?
The next expected earnings date for ProPhase Labs is 14 March 2025